219 related articles for article (PubMed ID: 9696656)
21. The glitazones: proceed with caution.
Krische D
West J Med; 2000 Jul; 173(1):54-7. PubMed ID: 10903299
[No Abstract] [Full Text] [Related]
22. Learning to use troglitazone.
Riddle MC
Diabetes Care; 1998 Sep; 21(9):1389-90. PubMed ID: 9727881
[No Abstract] [Full Text] [Related]
23. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
Imano E; Kanda T; Nakatani Y; Nishida T; Arai K; Motomura M; Kajimoto Y; Yamasaki Y; Hori M
Diabetes Care; 1998 Dec; 21(12):2135-9. PubMed ID: 9839106
[TBL] [Abstract][Full Text] [Related]
24. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
Hershon KS; Hershon PM
Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of troglitazone on body fat distribution in type 2 diabetes.
Akazawa S; Sun F; Ito M; Kawasaki E; Eguchi K
Diabetes Care; 2000 Aug; 23(8):1067-71. PubMed ID: 10937499
[TBL] [Abstract][Full Text] [Related]
26. Troglitazone: a new antihyperglycemic agent.
Vidt DG; Speerhas RA; Reddy SS
Cleve Clin J Med; 1997 May; 64(5):238-40. PubMed ID: 9149473
[TBL] [Abstract][Full Text] [Related]
27. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
[TBL] [Abstract][Full Text] [Related]
28. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.
Buse JB; Gumbiner B; Mathias NP; Nelson DM; Faja BW; Whitcomb RW
Diabetes Care; 1998 Sep; 21(9):1455-61. PubMed ID: 9727891
[TBL] [Abstract][Full Text] [Related]
29. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.
Horton ES; Whitehouse F; Ghazzi MN; Venable TC; Whitcomb RW
Diabetes Care; 1998 Sep; 21(9):1462-9. PubMed ID: 9727892
[TBL] [Abstract][Full Text] [Related]
30. Troglitazone and small low-density lipoprotein in type 2 diabetes.
Hirano T; Yoshino G; Kazumi T
Ann Intern Med; 1998 Jul; 129(2):162-3. PubMed ID: 9669982
[No Abstract] [Full Text] [Related]
31. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes.
Ebeling P; Teppo AM; Koistinen HA; Viikari J; Rönnemaa T; Nissén M; Bergkulla S; Salmela P; Saltevo J; Koivisto VA
Diabetologia; 1999 Dec; 42(12):1433-8. PubMed ID: 10651262
[TBL] [Abstract][Full Text] [Related]
32. Troglitazone's effect on lipoprotein(a) levels.
Ovalle F; Bell DS
Diabetes Care; 1999 May; 22(5):859-60. PubMed ID: 10332700
[No Abstract] [Full Text] [Related]
33. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.
Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
Diabetes Care; 1996 Feb; 19(2):151-6. PubMed ID: 8718436
[TBL] [Abstract][Full Text] [Related]
34. Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.
Gómez-Pérez FJ; Aguilar-Salinas CA; Vázquez-Chávez C; Fanghänel-Salmón G; Gallegos-Martínez J; Gómez-Diaz RA; Salinas-Orozco S; Chavira-López IJ; Sánchez-Reyes L; Torres-Acosta EM; Tamez R; López A; Guillén LE; Cesarman G
Metabolism; 2002 Jan; 51(1):44-51. PubMed ID: 11782871
[TBL] [Abstract][Full Text] [Related]
35. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
Bloomgarden ZT
Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
[No Abstract] [Full Text] [Related]
36. Efficacy of troglitazone measured by insulin resistance index.
Nagasaka S; Iwamoto Y; Ishikawa S; Kuzuya T; Saito T
Lancet; 1997 Jul; 350(9072):184. PubMed ID: 9250189
[No Abstract] [Full Text] [Related]
37. New diabetes drug targets insulin resistance.
Am J Health Syst Pharm; 1997 Mar; 54(6):623, 625. PubMed ID: 9075488
[No Abstract] [Full Text] [Related]
38. Increase of lipoprotein (a) with troglitazone.
Matsumoto K; Miyake S; Yano M; Ueki Y; Tominaga Y
Lancet; 1997 Dec; 350(9093):1748-9. PubMed ID: 9413470
[No Abstract] [Full Text] [Related]
39. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus.
Okazaki R; Miura M; Toriumi M; Taguchi M; Hirota Y; Fukumoto S; Fujita T; Tanaka K; Takeuchi A
Endocr J; 1999 Dec; 46(6):795-801. PubMed ID: 10724355
[TBL] [Abstract][Full Text] [Related]
40. Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients.
Fonseca V; Foyt HL; Shen K; Whitcomb R
Diabetes Care; 2000 Mar; 23(3):354-9. PubMed ID: 10868865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
